blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2363404

EP2363404 - PSMA antibodies [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.07.2017
Database last updated on 20.12.2024
Most recent event   Tooltip13.07.2018Lapse of the patent in a contracting state
New state(s): CY, MC, TR		published on 15.08.2018  [2018/33]
Applicant(s)For all designated states
PSMA Development Company L.L.C.
One World Trade Center
47th Floor Suite J
New York, NY 10007 / US
For all designated states
Amgen Fremont Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 / US
[2016/43]
Former [2016/38]For all designated states
PSMA Development Company L.L.C.
One World Trade Center
47th Floor Suite J
New York, NY 10007 / US
Former [2016/12]For all designated states
PSMA Development Company L.L.C.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
Former [2011/36]For all designated states
Psma Development Company, L.L.C.
Progenics Pharmaceuticals, 777 Old Saw Mill River Road Tarrytown
New York 10591 / US
Inventor(s)01 / Maddon, Paul, J.
191 Fox Meadow Road
Scarsdale, NY 10583 / US
02 / Donovan Gerald
1 Siler Lake Road
Kittery, ME 03904 / US
03 / Olson, William
815 Locke Lane
Yorktown Heights, NY 10598 / US
04 / Schulke, Norbert
37 Olympic Court
East Walpole, MA 02032 / US
05 / Gardner, Jason
320 Trillium Lane
Wayne, PA 19087 / US
06 / Ma, Dangshe
49 Gienwood Road
Millwood NY 10546 / US
 [2011/36]
Representative(s)Jump, Timothy John Simon, et al
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
[2016/36]
Former [2011/36]Jump, Timothy John Simon, et al
Venner Shipley LLP 20 Little Britain London
EC1A 7DH / GB
Application number, filing date10184938.823.10.2002
[2011/36]
Priority number, dateUS20010335215P23.10.2001         Original published format: US 335215 P
US20020362747P07.03.2002         Original published format: US 362747 P
US20020412618P20.09.2002         Original published format: US 412618 P
[2011/36]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2363404
Date:07.09.2011
Language:EN
[2011/36]
Type: A3 Search report 
No.:EP2363404
Date:25.01.2012
Language:EN
[2012/04]
Type: B1 Patent specification 
No.:EP2363404
Date:07.09.2016
Language:EN
[2016/36]
Type: B8 Corrected title page of specification 
No.:EP2363404
Date:07.12.2016
[2016/49]
Search report(s)(Supplementary) European search report - dispatched on:EP23.12.2011
ClassificationIPC:C07H21/04, C12N5/12, C07K16/00, A61K39/395, G01N33/53, A61K51/10, C07K16/30
[2012/04]
CPC:
A61K51/1096 (EP,US); A61K47/6825 (EP,US); A61K47/6869 (EP,US);
A61K51/1072 (EP,US); A61P13/08 (EP); A61P31/12 (EP);
A61P35/00 (EP); A61P37/02 (EP); A61P37/04 (EP);
A61P43/00 (EP); A61P9/00 (EP); C07K16/3069 (EP,US);
A61K2039/505 (EP,US); C07K2317/21 (EP,US); C07K2317/565 (EP,US);
C07K2317/622 (EP,US) (-)
Former IPC [2011/36]C07H21/04, C12N5/12, C07K16/00, A61K39/395, G01N33/53
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SK,   TR [2016/36]
Former [2011/36]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  IE,  IT,  LI,  LU,  MC,  NL,  PT,  SE,  SK,  TR 
Extension statesAL25.07.2012
LT25.07.2012
LV25.07.2012
MK25.07.2012
RO25.07.2012
SI25.07.2012
TitleGerman:PSMA Antikörper[2011/36]
English:PSMA antibodies[2011/36]
French:Anticorps contre le PSMA[2011/36]
Biological materialThis application mentions deposited biological material, check the file for details
Examination procedure25.07.2012Amendment by applicant (claims and/or description)
25.07.2012Examination requested  [2012/36]
11.02.2013Despatch of a communication from the examining division (Time limit: M06)
01.10.2013Reply to a communication from the examining division
11.07.2014Despatch of a communication from the examining division (Time limit: M06)
09.04.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
17.06.2015Reply to a communication from the examining division
09.03.2016Communication of intention to grant the patent
19.07.2016Fee for grant paid
19.07.2016Fee for publishing/printing paid
19.07.2016Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP02802198.8  / EP1448588
Divisional application(s)EP16187305.4  / EP3184539
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20020802198) is  30.10.2007
Opposition(s)08.06.2017No opposition filed within time limit [2017/33]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
17.06.2015Request for further processing filed
17.06.2015Full payment received (date of receipt of payment)
Request granted
29.06.2015Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
01.10.2013Request for further processing filed
01.10.2013Full payment received (date of receipt of payment)
Request granted
14.10.2013Decision despatched
Fees paidRenewal fee
24.01.2011Renewal fee patent year 03
24.01.2011Renewal fee patent year 04
24.01.2011Renewal fee patent year 05
24.01.2011Renewal fee patent year 06
24.01.2011Renewal fee patent year 07
24.01.2011Renewal fee patent year 08
24.11.2010Renewal fee patent year 09
25.10.2011Renewal fee patent year 10
25.10.2012Renewal fee patent year 11
28.10.2013Renewal fee patent year 12
27.10.2014Renewal fee patent year 13
27.10.2015Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT07.09.2016
BE07.09.2016
CY07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
FI07.09.2016
MC07.09.2016
SE07.09.2016
SK07.09.2016
TR07.09.2016
IE23.10.2016
LU23.10.2016
BG07.12.2016
GR08.12.2016
PT09.01.2017
[2018/29]
Former [2017/51]AT07.09.2016
BE07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
FI07.09.2016
SE07.09.2016
SK07.09.2016
IE23.10.2016
LU23.10.2016
BG07.12.2016
GR08.12.2016
PT09.01.2017
Former [2017/41]AT07.09.2016
BE07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
FI07.09.2016
SE07.09.2016
SK07.09.2016
LU23.10.2016
BG07.12.2016
GR08.12.2016
PT09.01.2017
Former [2017/34]AT07.09.2016
BE07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
FI07.09.2016
SE07.09.2016
SK07.09.2016
BG07.12.2016
GR08.12.2016
PT09.01.2017
Former [2017/23]AT07.09.2016
BE07.09.2016
CZ07.09.2016
EE07.09.2016
FI07.09.2016
SE07.09.2016
SK07.09.2016
BG07.12.2016
GR08.12.2016
PT09.01.2017
Former [2017/23]AT07.09.2016
BE07.09.2016
CZ07.09.2016
EE07.09.2016
FI07.09.2016
SE07.09.2016
SK07.09.2016
BG07.12.2016
GR08.12.2016
Former [2017/12]FI07.09.2016
SE07.09.2016
BE31.10.2016
GR08.12.2016
Former [2017/10]FI07.09.2016
SE07.09.2016
BE31.10.2016
Documents cited:Search[X]WO0109192  (MEDAREX INC [US], et al) [X] 1-16 * the whole document *;
 [X]  - DONOVAN G P ET AL, "ANTIBODY AND VACCINE THERAPIES TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, (20010324), vol. 42, ISSN 0197-016X, page 818, XP001204629 [X] 1-16 * the whole document *
 [XY]  - HOLMES E H, "PSMA specific antibodies and their diagnostic and therapeutic use", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, (200103), vol. 10, no. 3, ISSN 1354-3784, pages 511 - 519, XP002988381 [X] 1-16 * the whole document * [Y] 17

DOI:   http://dx.doi.org/10.1517/13543784.10.3.511
 [X]  - LIU H ET AL, "MONOCLONAL ANTIBODIES TO THE EXTRACELLULAR DOMAIN OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALSO REACT WITH TUMOR VASCULAR ENDOTHELIUM", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (19970901), vol. 57, no. 17, ISSN 0008-5472, pages 3629 - 3634, XP001080132 [X] 1-16 * the whole document *
 [Y]  - GONG M C ET AL, "Prostate-specific membrane antigen (PMSA)-specific monoclonal antibodies in the treatment of prostate and other cancers", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, (1999), vol. 18, no. 4, ISSN 0167-7659, pages 483 - 490, XP002982445 [Y] 1-16 * the whole document *
 [Y]  - SMITH-JONES P M ET AL, "In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (20000915), vol. 60, no. 18, ISSN 0008-5472, pages 5237 - 5243, XP002327842 [Y] 1-16 * the whole document *
 [A]  - LAPIDUS RENA G ET AL, "Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells", PROSTATE, WILEY-LISS, NEW YORK, NY, US, (20001201), vol. 45, no. 4, ISSN 0270-4137, pages 350 - 354, XP009026666 [A] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1002/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO;2-U
 [XY]  - TINO WILLIAM T ET AL, "Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA)", HYBRIDOMA, (200006), vol. 19, no. 3, ISSN 0272-457X, pages 249 - 257, XP002397386 [X] 1-16 * the whole document * [Y] 17

DOI:   http://dx.doi.org/10.1089/02724570050109648
 [T]  - SCHULKE N ET AL, "The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (20031028), vol. 100, no. 22, ISSN 0027-8424, pages 12590 - 12595, XP002323660 [T] * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.1735443100
by applicantUS5124471
 US5162504
 US5286850
 US5434287
 US5538866
 US5545806
 US5545807
 US5591669
 US5598369
 US5756825
 US5994292
 US6034065
 US6150584
 US6158508
 US6239104
    - LANDIS, S.H. ET AL., CA CANCER ,J CLIRA., (1998), vol. 48, pages 6 - 29
    - PARKER ET AL., CA CANCER J. CLIN., (1997), vol. 47, pages 5 - 280
    - WINGO ET AL., CA CARACER J. CLIN., (1996), vol. 46, pages 113 - 25
    - HOROSZEWICZ ET AL., ANTICANCER RES., (1987), vol. 7, pages 927 - 935
    - WRIGHT ET AL., ANTIBODY IMMUNOCONJUGATES AND RADIO PHARMACEUTICALS, (1990), page 3
    - ISRAELI ET AL., CANCER RES., (1994), vol. 54, pages 1807 - 1811
    - CARTER ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1996), vol. 93, pages 749 - 753
    - ROCHON ET AL., PROSTATE, (1994), vol. 25, pages 219 - 223
    - MURPHY ET AL., PROSTATE, (1995), vol. 26, pages 164 - 168
    - MURPHY ET AL., ANTICANCER RES., (1995), vol. 15, pages 1473 - 1479
    - Current Protocols in Molecular Biology, JOHN WILEY & SONS, INC.
    - WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546
    - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
    - J. GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1983), pages 98 - 118
    - GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 60 - 61
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495
    - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, INC., (1995), pages 77 - 96
    - GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 65 - 66
    - CAMPBELL, Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology, ELSEVIEW, (1984), vol. 13, pages 75 - 83
    - MILSTEIN; KOHLER, EUR. J. IMMUNOL., (1976), vol. 6, page 511
    - WALDMANN, SCIENCE, (1991), vol. 252, page 1657
    - HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - POIJAK, R.J. ET AL., STRUCTURE, (1994), vol. 2, pages 1121 - 1123
    - FANGER ET AL., DRUG NEWS & PETSPEC., (1995), vol. 8, no. 3, pages 133 - 137
    - BAERGA-ORTIZ ET AL., PROTEIN SCIENCE, (2002), vol. 11, pages 1300 - 1308
    - Current Protocols in Immunology, JOHN WILEY & SONS
    - PETTIT, G.R. ET AL., ANTICANCER DRUG DES., (1998), vol. 13, no. 4, pages 243 - 277
    - WOYKE, T. ET AL., ANTIMICROB. AGENTS CHEMOTHER., (2001), vol. 45, no. 12, pages 3580 - 3584
    - GRIGGS ET AL., LANCET ONCOL., (2001), vol. 2, page 82
    - ROSEN, ONCOLOGIST, (2000), vol. 5, page 20
    - KERBEL, J. CLIN. ONCOL., (2001), vol. 19, no. 18S, pages 45S - 51S
    - DEAL ET AL., 1. MED. CLIENT., (1999), vol. 42, page 2988
    - MCDEVITT ET AL., SCIENCE, (2001), vol. 294, pages 1537 - 1540
    - BIEDERER, C. ET AL., J. MOL. MED., (2002), vol. 80, no. 3, pages 163 - 175
    - BERGE, S.M. ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING CO.
    - "Aerosols", SCIARRA; CUTIE, Remington's Pharmaceutical Sciences, (1990), pages 1694 - 1712
    - BASLYA; MENDELSOHN, BREAST CANCER RES. AND TREATMENT, (1994), vol. 29, pages 127 - 138
    - VITETTA; UHR, ANNU. REV. IMMUNOL., (1985), vol. 3, page 197
    - KREIG ET AL., NATURE, (1995), vol. 374, pages 546 - 9
    - SCIENCE, (1995), vol. 268, pages 1432 - 1434
    - FRIEDEN, J. BIOL, CHEM., (1959), vol. 234, page 2891
    - CLIN. CANCER RES., (1996), vol. 2, no. 9, pages 1445 - 51
    - UROLOGY, (1997), vol. 49, no. 3A, pages 104 - 12
    - O'KEEFE ET AL., Prostate Cancer: Biology, Genetics, and the New Therapeutics, HUMANA PRESS, (2000), pages 307 - 326
    - ISRAELI ET AL., CANCER RES., (1993), vol. 53, pages 227 - 230
    - TRKOLA ET AL., NATURE, (1996), vol. 384, pages 184 - 187
    - MENDEZ ET AL., NATURE GENETICS, (1997), vol. 15, page 146
    - LIU, H. ET AL., CANCER RES., (1997), vol. 57, pages 3629 - 3634
    - CHANG, S.S. ET AL., CANCER RES., (1999), vol. 59, pages 3192 - 3198
    - MURPHY, G.P. ET AL., J UROLOGY, (1998), vol. 160, pages 2396 - 2401
    - LIU, H. ET AL., CANCER RES, (1997), vol. 57, pages 3629 - 3634
    - HESTON, W.D.W., Prostate: Basic and Clinical Aspects, CRC PRESS, (1997), pages 219 - 243
    - PINTO, J.T. ET AL., CLINICAL CANCER RES, (1996), vol. 2, pages 1445 - 1451
    - O'KEEFE D.S. ET AL., PROSTATE, (2000), vol. 45, pages 149 - 157
    - SILVER, D.A. ET AL., CLIN CANCER RES, (1997), vol. 3, pages 81 - 85
    - BRECHBIEL, M.W. ET AL., J. CHEM. SOC. CHEM. COMMUN., (1991), pages 1169 - 1170
    - MCDEVITT, M.R. ET AL., J. NUCL. MED., (1999), vol. 40, pages 1722 - 1727
    - DEAL, K.A. ET AL., J. MED. CHEM., (1999), vol. 42, pages 2988 - 2992
    - NIKULA, T.K. ET AL., NUCL. MED. BIOL., (1995), vol. 22, pages 3 87 - 390
    - PIPPIN, C.G. ET AL., BIOCONJUGATE CHEMISTRY, (1992), vol. 3, pages 342 - 345
    - ZAMORA, P.O. ET AL., BIOTECHNIQUES, (1994), vol. 16, pages 306 - 311
    - SCHEINBERG, D.A. ET AL., LEUKEMIA, (1991), vol. 3, pages 440 - 445
    - CARON, P.C. ET AL., CANCER RES, (1992), vol. 52, pages 6761 - 6767
    - SMITH-JONES P.M. ET AL., CANCER RES, (2000), vol. 60, pages 5237 - 5243
    - NIKULA, T.K. ET AL., J. NUCL. MED., (1999), vol. 40, pages 166 - 176
    - MCDEVITT, M.R. ET AL., EUR. J. NUCL. MED., (1998), vol. 25, pages 1341 - 1351
    - O'CONNOR, K.C., PHARM. RES., (1999), vol. 16, pages 486 - 493
    - BALLANGRUD, A.M. ET AL., CLIN, CANCER RES., (1999), vol. 5, pages 3171S - 3176S
    - ELLIS, W.J. ET AL., CLIN CANCER RES, (1996), vol. 2, pages 1039 - 1048
    - WAINSTEIN, M.A. ET AL., CANCER RES, (1994), vol. 54, pages 6049 - 6052
    - NAGABHUSHAN, M. ET AL., CANCER RES, (1996), vol. 56, pages 3042 - 3046
    - PRETLOW, T.G. ET AL., JNATL CANCE; INST, (1993), vol. 85, pages 394 - 398
    - PINTO ET AL., CLINICAL CANCER RESEARCH, (1996), vol. 2, page 1445
    - ISRAELI ET AL., CANCER RESEARCH, (1994), vol. 54, page 1807
    - TROYER ET AL., INT. ,/ CANCER, (1995), vol. 62, page 552
    - TROYER ET AL., THE PROSTATE, (1997), vol. 30, page 233
    - GRAUER ET AL., CANCER RESEARCH, (1998), vol. 58, page 4787
    - SCHAGGER; V. JAGOW, ANAL. BIOCHEM., (1991), vol. 199, pages 223 - 231
    - SCHäGGER ET AL., ANAL. BIOCHEM., (1994), vol. 217, pages 220 - 230
    - SPENO ET AL., MOLECULAR PHARMACOLOGY, (1999), vol. 55, page 179
    - BERGAMASCHI, G.; PERFETTI, V.; TONON, L.; NOVELLA, A.; LUCOTTI, C.; DANOVA, M.; GLENNIE, M.J.; MERLINI, G.; CAZZOLA, M., "Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis", BR J HAEMATOL, (1996), vol. 93, pages 789 - 94
    - WRENN ET AL., BRAIN RES., (1996), vol. 740, pages 175 - 184
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.